Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Do all hormone sensitive prostate cancers need triplet therapy?

ESMO 2025: Precision medicine in bladder cancer

Best practice in precision medicine for prostate cancer

ctDNA-guided adjuvant atezolizumab improves OS in MIBC

ctDNA-guided adjuvant chemo de-escalation reduces toxicity with comparable outcomes in stage III colon cancer

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others

Key insights from lung cancer research at ASCO 2025

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC